Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AG-236 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Group A | EXPERIMENTAL | Participants will receive a single dose of AG-236 at dose level 1 or placebo on Day 1 under fasted conditions. |
| Treatment Group B | EXPERIMENTAL | Participants will receive a single dose of AG-236 at dose level 2 or placebo on Day 1 under fasted conditions. |
| Treatment Group C | EXPERIMENTAL | Participants will receive a single dose of AG-236 at dose level 3 or placebo on Day 1 under fasted conditions. |
| Name | Type | Description |
|---|---|---|
| AG-236 | DRUG | Subcutaneous (SC) Injection |
| Placebo | DRUG | SC Injection |
Inclusion Criteria * Male or female, of any race, between 18 and 55 years of age, inclusive. 1. Females must be of nonchildbearing potential. 2. Males must agree to use contraception. 3. Males must agree not to donate sperm during the study and for 90 days or 5-half-lives of AG-236 in plasma...
AG-236 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development to evaluate its safety, tolerability, and how it is absorbed, broken down, and eliminated from the body. It is not approved for any medical condition.
AG-236 is being developed by Agios Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker AGIO. The company is conducting a Phase 1 clinical trial to assess the drug's safety and pharmacokinetics in healthy participants.
AG-236 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 study is designed to evaluate its safety, tolerability, and how the body processes the drug in healthy participants.
AG-236 is being studied in one active Phase 1 clinical trial, NCT07075640. This trial is a randomized, double-blind, controlled study in healthy participants in the United States, with an enrollment of 24 individuals aged 18 years and older. The study is active but not currently recruiting.
No alternative names for AG-236 have been reported. It is identified solely by its code name AG-236 in clinical trial registries and is being developed by Agios Pharmaceuticals. No other names or aliases are associated with this investigational drug.